Medtronic Inc. (NYSE:MDT) announced Wednesday that it is offering a $2.5 million grant to Yale researchers who will independently review the safety of the company’s controversial Infuse bone graft product.
The funds will cover two reviews of the so-called recombinant bone morphogenic protein-2 (rhBMP-2) product, which stimulates bone formation. Yale expects to complete the reviews in six months.